ClinicalTrials.gg
CompletedNCT07849166Updated Sep 30, 2026

BRCC36 and Telomerase Levels in Women With Polycystic Ovary Syndrome

An observational study in Polycystic Ovarian Syndrome (PCOS), sponsored by Cumhuriyet University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 43 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Cumhuriyet University · Observational

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
60
Ages
18 Years to 43 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Polycystic Ovary Syndrome with a site in Turkey — 14 open to participants now, 15 under way, none of them phase 3. Polycystic Ovary Syndrome · Turkey.

Enrollment
36th of 43
60 · median 90
Started
2024
with 9 others
Observational
43 of 72
4 open now
Registered
68th of 72
by date

Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, this one is the 36th largest by enrollment of the 43 observational ones that give a count, is one of 10 that started in 2024, is one of 43 observational ones, and was the 68th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

14 of the 72 studies in Polycystic Ovary Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 43 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Polycystic Ovary Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

This prospective observational case-control study evaluated serum BRCC36 and telomerase (TE) levels in women with polycystic ovary syndrome (PCOS) and healthy controls. Women aged 18-43 years were included. The study comprised 30 women diagnosed with PCOS according to ESHRE/ASRM criteria and 30 healthy women with regular menstrual cycles. A single 5-mL venous blood sample was collected from each participant. Serum was separated by centrifugation and stored at -80°C until analysis. Serum BRCC36 and telomerase levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The study evaluated differences in these biomarkers between women with PCOS and healthy controls and their relationships with clinical and biochemical characteristics.

Read the detailed description

This prospective observational case-control study included women aged 18-43 years with polycystic ovary syndrome (PCOS) and healthy controls. PCOS was diagnosed according to ESHRE/ASRM criteria based on the presence of at least two of the following features: oligo- and/or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasonography.

Participants underwent clinical and anthropometric evaluation, including body mass index and modified Ferriman-Gallwey scoring. Available biochemical and hormonal parameters obtained during routine clinical evaluation were also recorded.

For the study-specific biomarker analyses, a single 5-mL venous blood sample was collected from each participant into a serum separator tube. Samples were centrifuged at 3000 rpm for 10 minutes, and the separated sera were stored at -80°C until analysis. Serum BRCC36, a deubiquitinating enzyme-related biomarker, and telomerase (TE) levels were measured using commercially available human ELISA kits.

The primary objective was to compare serum BRCC36 and telomerase levels between women with PCOS and healthy controls. Associations between these biomarkers and clinical and biochemical characteristics were also evaluated.

03

Conditions studied

  • Polycystic Ovarian Syndrome (PCOS)

Keywords

  • BRCC36
  • Telomerase
  • Deubiquitinating Enzymes
  • Polycystic Ovary Syndrome
  • Biomarkers
04

Who can participate

Ages eligible
18 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women aged 18-43 years attending Sivas Cumhuriyet University Faculty of Medicine Hospital were included. The study population consisted of 30 women diagnosed with PCOS according to ESHRE/ASRM criteria and 30 healthy women with regular menstrual cycles who served as controls. All participants were non-obese (BMI \<30 kg/m²) and provided written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-43 years.
  • PCOS group: diagnosis of PCOS according to ESHRE/ASRM criteria, based on the presence of at least two of the following: oligo- and/or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology.
  • Control group: healthy women with regular menstrual cycles (21-35 days), modified Ferriman-Gallwey score \<8, and no unilateral or bilateral polycystic ovarian morphology on pelvic ultrasonography.
  • \<30 kg/m².
  • No oral use during the study period or within the previous 6 months.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Thyroid dysfunction, prolactinoma, Cushing disease, or late-onset congenital adrenal hyperplasia.
  • Diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, or renal or hepatic dysfunction.
  • Additional gynecological disease.
  • Use of medications affecting sex hormone or carbohydrate metabolism.
  • Inadequate or unsuitable blood/serum sample for laboratory analysis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
60 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • PCOS Group

    Women aged 18-43 years diagnosed with polycystic ovary syndrome according to ESHRE/ASRM criteria (n=30).

  • Healthy Control Group

    Healthy women aged 18-43 years with regular menstrual cycles and without clinical or ultrasonographic features of PCOS (n=30).

06

What researchers measure

Primary outcomes

  1. Serum BRCC36 Level

    Serum BRCC36 levels measured using a commercially available human ELISA kit and compared between the PCOS and healthy control groups.

    Time frame: At study enrollment (single blood collection)

  2. Serum Telomerase Level

    Serum telomerase (TE) levels measured using a commercially available human ELISA kit and compared between the PCOS and healthy control groups.

    Time frame: At study enrollment (single blood collection)

07

Study locations

1 site
  • Sivas Cumhuriyet University
    Sivas, Sivas, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — maybe after de article submission i will plan to share.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Feb 2025, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartActual
Feb 20, 2024
Primary completionActual
Feb 20, 2025
CompletionActual
May 1, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849166
Responsible party
Dilara Ulger Ozbek (Asistant Professor, Cumhuriyet University) — Principal investigator
First posted
Sep 30, 2026
Start date
Feb 20, 2024
Primary completion
Feb 20, 2025
Completion
May 1, 2026
Last update
Sep 30, 2026

Study contacts

Dilara Ülger Özbek, PhD
principal investigator · Cumhuriyet University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion